Interestingly, data derived from pre-clinical mouse models and clinical trials showed that inhibition of the PI3K-AKT signaling pathway could increase tumor immunosurveillance by improving immune anti-tumor properties and prevent immunosuppression. Here, AKT1 is linked to neoplasm.